Please login to the form below

Not currently logged in
Email:
Password:

Sativex

This page shows the latest Sativex news and features for those working in and with pharma, biotech and healthcare.

GW Pharma's cannabis-based medicine to be tested in dementia

GW Pharma's cannabis-based medicine to be tested in dementia

dementia. Sativex, which is approved to treat MS, is a peppermint-flavoured mouth spray that contains a 1:1 ratio of two key cannabinoids found in the cannabis plant. ... We will also get some indication of whether Sativex is effective at reducing

Latest news

  • Medical cannabis now available on prescription, for some Medical cannabis now available on prescription, for some

    It already has approval for an oral spray product called Sativex in the UK and other European markets as a treatment for spasticity associated with MS, but this product isn’t

  • US approval for first ever cannabis-based medicine US approval for first ever cannabis-based medicine

    The company’s first CBD product was Sativex, first approved over a decade ago, but Epidiolex has built up a more compelling evidence base in these hard-to-treat conditions.

  • GW ascendant as epilepsy drug clears phase III trial GW ascendant as epilepsy drug clears phase III trial

    GW already makes fees and royalty revenues from cannabinoid-based drug called Sativex for moderate to severe spasticity in multiple sclerosis patients who have not responded adequately to other anti-spasticity

  • NICE denies two drugs in new MS guidance NICE denies two drugs in new MS guidance

    process”. Sativex. Sativex is licensed to treat moderate to severe spasticity in MS patients who have not responded adequately to other anti-spasticity medication. ... conduct a full technology appraisal of Sativex, meaning a more “thorough and

  • Cancer pain: opioids set to dominate Cancer pain: opioids set to dominate

    Phase III: opioid agonists. GW Pharmaceuticals has developed a buccal spray known as nabiximols or Sativex, which comprises delta-9-tetrahydrocannabinol (27mg/mL) and cannabidiol (25mg/mL), as an analgesic agent

More from news
Approximately 4 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Death by Numbers Death by Numbers

    Not so. Take the example of this campaign for Sativex, a drug used in the treatment of Multiple Sclerosis. ... The obvious solution to the brief was an ingredient story - Sativex is derived from cannabis.

  • Interview: Jorge Gallardo, Almirall Interview: Jorge Gallardo, Almirall

    Also in 2011, we have launched Sativex,  an oral spray for spasticity in multiple sclerosis, which will be deployed in Europe soon.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis ... This is an exciting time to be joining GW, with

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics